A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors

Phase 1 Recruiting 137 enrolled CD (Suzhou) Biopharma Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Timeline

Start: 2025-01-08
Primary completion: 2028-01
Completion: 2028-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD-001	Unknown	—	Intravenous

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications